Prospective Randomized Comparison of Intravesical with Percutaneous Bacillus Calmette-Guerin Versus Intravesical Bacillus Calmette-Guerin in Superficial Bladder Cancer

No AccessJournal of Urology1 Apr 1991Prospective Randomized Comparison of Intravesical with Percutaneous Bacillus Calmette-Guerin Versus Intravesical Bacillus Calmette-Guerin in Superficial Bladder Cancer Donald L. Lamm, Jean I. DeHaven, Jackie Shriver, and Michael F. Sarosdy Donald L. LammDonald L. Lamm , Jean I. DeHavenJean I. DeHaven , Jackie ShriverJackie Shriver , and Michael F. SarosdyMichael F. Sarosdy View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)38439-2AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Conflicting reports of the necessity for percutaneous bacillus Calmette-Guerin (BCG) administration with intravesical BCG prompted us to evaluate its benefit in a randomized prospective comparison of intravesical versus intravesical with percutaneous BCG therapy. Intravesical Tice BCG was given in a dose of 50mg. with or without percutaneous BCG weekly for 6 weeks, at 8, 10 and 12 weeks, at 6 months and every 6 months thereafter. Tumor recurrence was documented in 13 of 30 patients (43%) receiving only intravesical BCG and in 15 of 36 patients (42%) receiving intravesical plus percutaneous BCG. The addition of percutaneous BCG to intravesical therapy did not increase treatment efficacy in this study. © 1991 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byPEYROMAURE M, GUERIN F, AMSELLEM-OUAZANA D, SAIGHI D, DEBRE B and ZERBIB M (2018) Intravesical Bacillus Calmette-Guerin Therapy for Stage T1 Grade 3 Transitional Cell Carcinoma of the Bladder: Recurrence, Progression and Survival in a Study of 57 PatientsJournal of Urology, VOL. 169, NO. 6, (2110-2112), Online publication date: 1-Jun-2003.LAMM D, BLUMENSTEIN B, CRISSMAN J, MONTIE J, GOTTESMAN J, LOWE B, SAROSDY M, BOHL R, GROSSMAN H, BECK T, LEIMERT J and CRAWFORD E (2018) MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDYJournal of Urology, VOL. 163, NO. 4, (1124-1129), Online publication date: 1-Apr-2000.Luftenegger W, Ackermann D, Futterlieb A, Kraft R, Minder C, Nadelhaft P and Studer U (2018) Intravesical Versus Intravesical Plus Intradermal Bacillus Calmette-Guerin: A Prospective Randomized Study In Patient With Recurrent Superficial Bladder TumorsJournal of Urology, VOL. 155, NO. 2, (483-487), Online publication date: 1-Feb-1996.Lamm D, Riggs D, Shriver J, vanGilder P, Rach J and DeHaven J (2018) Megadose Vitamins in Bladder Cancer: A Double-Blind Clinical TrialJournal of Urology, VOL. 151, NO. 1, (21-26), Online publication date: 1-Jan-1994.Mizutani Y, Nio Y, Fukumoto M and Yoshida O (2018) Enhanced Antitumor Effect of Bacillus Calmette-Guérin in Combination with Fibrinogen on Urinary Bladder TumorJournal of Urology, VOL. 151, NO. 5, (1420-1426), Online publication date: 1-May-1994.Böhle A, Kirsten D, Schröder K, Knipper A, Fornara P, Magnussen H and Jocham D (2018) Clinical Evidence of Systemic Persistence of Bacillus Calmette-Guerin: Long-Term Pulmonary Bacillus Calmette-Guerin Infection After Intravesical Therapy for Bladder Cancer and Subsequent CystectomyJournal of Urology, VOL. 148, NO. 6, (1894-1897), Online publication date: 1-Dec-1992. Volume 145Issue 4April 1991Page: 738-740 Advertisement Copyright & Permissions© 1991 by The American Urological Association Education and Research, Inc.KeywordscarcinomaBCG vaccinebladder neoplasmstransitional cellMetricsAuthor Information Donald L. Lamm More articles by this author Jean I. DeHaven More articles by this author Jackie Shriver More articles by this author Michael F. Sarosdy More articles by this author Expand All Advertisement PDF downloadLoading ...